

REFERENCES

1. Tay J, Masini G, McEniery CM, et al. Uterine and fetal placental Doppler indices are associated with maternal cardiovascular function. *Am J Obstet Gynecol* 2019;220:96.

2. Foo FL, Mahendru AA, Masini G, et al. Association between pre-pregnancy cardiovascular function and subsequent preeclampsia or fetal growth restriction. *Hypertension* 2018;72:442–50.

© 2019 Elsevier Inc. All rights reserved. <https://doi.org/10.1016/j.ajog.2019.06.012>

Revitalizing research in genitourinary syndrome of menopause



TO THE EDITORS: The call to action by Chang and Paraiso¹ highlighted the many barriers to women wishing relief of post-menopausal sexual dysfunction stemming from genitourinary syndrome of menopause (GSM). Even when gaining advice from knowledgeable care providers, women find the costs of effective local and systemic therapies to be prohibitive. Therapies now too expensive for many women include hormonal options that have been available for decades, as well as new energy-based therapies whose efficacy and safety have not passed FDA muster.²

The authors repeated a now-challenged prohibition against low-dose local estrogen products in women with a history of estrogen-sensitive breast cancer, but these were deemed safe by experts in the American College of Obstetricians and Gynecologists.³ Despite this shift in recommendations, most survivors choose to forego hormones even after developing very difficult genitourinary symptoms.

Physicians should realize that there is an inexpensive, self-applied option that has been shown to be extremely helpful in a randomized controlled trial.⁴ Patients successfully used a topical numbing solution to prevent moderate and severe dyspareunia after menopause. After a 3-minute application using cotton balls, penetration pain scores dropped on average from 8 out of 10 to 1 out of 10 with use of lidocaine 4% topical solution applied to the vulvar vestibule just before intimacy. GSM is not simply atrophy, but includes a pain condition specific to the vulvar vestibule. Numbing therapy may seem counterproductive for pleasure, but the location is discrete and small, and women can extinguish mucosal pain but still enjoy wider genital sensations. Arousal success and orgasm quality increased when pain was prevented. Partners did not note any numbing, and couples rejoiced at being able to return to pain-free coitus after half of them had previously abandoned painful penetrative sex.

Even lidocaine is not without its price explosion in the last several years. This old off-patent medication that used to cost \$8.50 by prescription for a 50 mL bottle now approaches a 10 times higher price. There are over-the-counter gel and cream products with the same 4% concentration of lidocaine, but studies have not been published on use in this population.

While the health care system in the United States grapples with prescription drug costs, patients can be directed to this effective, low-cost, nonhormonal option rather than sitting out penetrative intimacy during postmenopausal years. The lidocaine option was studied in breast cancer survivors

because they so typify the difficulties that arise with estrogen deprivation. But any GSM patient may find this therapy beneficial. I wonder if the authors agree that it is time to share information about self-applied anesthetic products for GSM and continue studying outcomes. ■

Martha F. Goetsch, MD, MPH
Program in Vulvar Health
Department of Obstetrics and Gynecology
Oregon Health and Science University
Portland, OR
goetsch@ohsu.edu

The author reports no conflict of interest and no sources of financing.

REFERENCES

1. Chang OH, Paraiso MFR. Revitalizing research in genitourinary syndrome of menopause. *Am J Obstet Gynecol* 2019;220:246–8.

2. Letters to Industry: to Cynosure, Inc. Available at: <https://www.fda.gov/files/medical%20devices/published/Cynosure-Inc.-Letter-July-24-2018.pdf>. Accessed July 17, 2019.

3. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Committee Opinion No. 659. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2016;127:e93–6.

4. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. *J Clin Oncol* 2015;33:3394–400.

© 2019 Elsevier Inc. All rights reserved. <https://doi.org/10.1016/j.ajog.2019.06.016>

REPLY



We would like to thank Dr Goetsch for her Letter to the Editors (L19-053AR1). In our Call to Action—“Revitalizing research in genitourinary syndrome of menopause”¹—we discussed the barriers and limitations to the treatment of genitourinary syndrome of menopause (GSM) in light of the FDA 2018 statement cautioning women against vaginal rejuvenation devices.

We discussed the limitations with the use of vaginal estrogen in women with a history of hormone-sensitive breast cancer. The American College of Obstetricians and Gynecologists recommends trialing nonhormonal treatment options for vaginal atrophy in this population, owing to the lack of long-term data on hormone treatments (level C recommendation).^{2,3}

In our practice, we initiate women with a history of hormone-sensitive breast cancer with nonhormonal vaginal lubricants or moisturizers,^{4,5} with consideration of energy-based therapy. In women with persistent or refractory symptoms, we will consider initiating these women on vaginal estrogen, but only after consulting with their oncologist. We agree with Dr Goetsch that many breast cancer survivors are reluctant to initiate vaginal estrogen, which further highlights the importance of innovation and research in the field of GSM.

In regard to the use of self-applied anesthetic, we prescribe topical lidocaine for dyspareunia for women suffering from vestibulitis or vulvodynia, or for women with superficial dyspareunia. We have found success in this population, as many patients are able to have intercourse. With Dr Goetsch's research on this topic in breast cancer survivors, it is reassuring that pain from penetrative intercourse dropped after self-application with topical lidocaine.⁶ We agree that continued research on self-applied anesthetic products for GSM is warranted. While this therapy is useful for symptomatic relief, it does not reverse the loss of vaginal elasticity and thinning of vaginal epithelial tissue. Additional therapy may be needed to address postcoital vaginal fissures and pain.

Overall, we recognize the numerous leaders in the field of menopause and vulvar health, who contribute high-quality research to improve the lives of women with GSM. As discussed in our Call to Action, we want to motivate our colleagues to continue their tenacious efforts to ensure women can find relief from genitourinary syndrome of menopause. ■

Olivia H. Chang, MD, MPH
Section of Female Pelvic Medicine and Reconstructive Surgery
Department of Obstetrics and Gynecology
Cleveland Clinic Foundation
Cleveland, OH
chango@ccf.org

Marie Fidela R. Paraiso, MD
Section of Female Pelvic Medicine and Reconstructive Surgery
Department of Obstetrics and Gynecology
Cleveland Clinic Foundation
Cleveland, OH

The authors report no conflict of interest.

REFERENCES

1. Chang OH, Paraiso MFR. Revitalizing research in genitourinary syndrome of menopause. *Am J Obstet Gynecol* 2019;220:246.e1–4.
2. American College of Obstetricians and Gynecologists. Practice Bulletin 126. *Obstet Gynecol* 2012;119:666–82.
3. American College of Obstetricians and Gynecologists. Practice Bulletin No. 141. *Obstet Gynecol* 2014;123:202–16.
4. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. *Maturitas* 1996;23:259–63.
5. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. *J Clin Oncol* 1997;15:969–73.
6. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. *J Clin Oncol* 2015;33:3394–400.

© 2019 Elsevier Inc. All rights reserved. <https://doi.org/10.1016/j.ajog.2019.06.017>